PMID- 30066497
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 7
IP  - 9
DP  - 2018 Sep
TI  - Clinical benefit of treatment with eribulin mesylate for metastatic 
      triple-negative breast cancer: Long-term outcomes of patients treated in the US 
      community oncology setting.
PG  - 4371-4378
LID - 10.1002/cam4.1705 [doi]
AB  - INTRODUCTION: Real-world data are critical to demonstrate the consistency of 
      evidence and external generalizability of randomized controlled trials (RCTs). 
      This study examined characteristics and outcomes of metastatic triple-negative 
      breast cancer (mTNBC) patients treated with eribulin mesylate at community 
      oncology practices in the United States. METHODS: Physicians identified mTNBC 
      patients initiating eribulin between 1 January 2011 and 1 January 2014 and 
      abstracted data into an electronic case report form (eCRF). Eribulin treatment in 
      the metastatic setting was categorized as early use (EU, first-/second-line) and 
      late use (LU, third-line or later). Patient characteristics, overall survival 
      (OS), disease response (per treating physician), and adverse events (AEs) rates 
      in each group, respectively, are reported. RESULTS: Overall 252 eCRFs were 
      completed: 125 (49.6%) EU and 127 (50.4%) LU. The median age at metastatic 
      diagnosis was 53 years and 42.1% were stage IV at their initial diagnosis. The 
      median duration of follow-up from the initiation of first-line treatment was 
      24 months. Rates of disease response (complete or partial per treating physician) 
      were 69.9% in the EU group and 48.8% in the LU group. The five most commonly 
      reported adverse events during eribulin were as follows: fatigue (65.1%), 
      weakness (40.1%), decreased appetite (32.5%), neutropenia (31.0%), and leukopenia 
      (27.4%). Discontinuation of eribulin due to AE was observed in 4.0% of patients. 
      Median OS from initiation of eribulin was 23.0 months (95% CI: 18.7-27.3) among 
      EU and 14.7 (95% CI: 12.6-16.9) among LU. CONCLUSION: In the real-world 
      eribulin-treated mTNBC, patients have more sites of metastatic disease and 
      exposure to greater numbers of prior therapies compared to RCTs. The median OS of 
      14.7 months among LU patients is consistent with, and slightly longer than the 
      13.1 months and 14.4 months reported in the EMBRACE and Study 301 clinical 
      trials, respectively.
CI  - (c) 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Mougalian, Sarah S
AU  - Mougalian SS
AUID- ORCID: 0000-0002-8837-1425
AD  - Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
FAU - Copher, Ronda
AU  - Copher R
AD  - Eisai Inc., Woodcliff Lake, New Jersey.
FAU - Kish, Jonathan K
AU  - Kish JK
AD  - Cardinal Health Specialty Solutions, Dallas, Texas.
FAU - McAllister, Lindsay
AU  - McAllister L
AD  - Cardinal Health Specialty Solutions, Dallas, Texas.
FAU - Wang, Zhixiao
AU  - Wang Z
AD  - Eisai Inc., Woodcliff Lake, New Jersey.
FAU - Broscious, Mary
AU  - Broscious M
AD  - Cardinal Health Specialty Solutions, Dallas, Texas.
FAU - Garofalo, David
AU  - Garofalo D
AD  - Cardinal Health Specialty Solutions, Dallas, Texas.
FAU - Radtchenko, Janna
AU  - Radtchenko J
AD  - Cardinal Health Specialty Solutions, Dallas, Texas.
FAU - Feinberg, Bruce A
AU  - Feinberg BA
AD  - Cardinal Health Specialty Solutions, Dallas, Texas.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180731
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Furans)
RN  - 0 (Ketones)
RN  - LR24G6354G (eribulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Furans/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Ketones/administration & dosage/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Triple Negative Breast Neoplasms/*drug therapy/mortality/*pathology
MH  - United States
PMC - PMC6144147
OTO - NOTNLM
OT  - eribulin
OT  - metastatic breast cancer
OT  - real-world
OT  - survival
OT  - triple negative
EDAT- 2018/08/02 06:00
MHDA- 2019/11/15 06:00
PMCR- 2018/07/31
CRDT- 2018/08/02 06:00
PHST- 2018/03/27 00:00 [received]
PHST- 2018/06/19 00:00 [revised]
PHST- 2018/06/28 00:00 [accepted]
PHST- 2018/08/02 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
PHST- 2018/08/02 06:00 [entrez]
PHST- 2018/07/31 00:00 [pmc-release]
AID - CAM41705 [pii]
AID - 10.1002/cam4.1705 [doi]
PST - ppublish
SO  - Cancer Med. 2018 Sep;7(9):4371-4378. doi: 10.1002/cam4.1705. Epub 2018 Jul 31.